A DOUBLE-BLIND, ACTIVE-COMPARATOR 7-DAY ENDOSCOPIC TRIAL OF LT-NS001, A NAPROXEN PRO-DRUG, DEMONSTRATING A SIGNIFICANT DECREASE IN TOTAL MODIFIED GASTRODUODENAL LANZA SCORE AND GASTRIC ULCER RATE COMPARED WITH NAPROSYN.®

(1) Gastroenterology, University of Illinois at Chicago, Chicago IL, United States

(2) Gastroenterology, EGK Sanatorium, Prague, Czech Republic

(3) Gastroenterology, Gastroenterology Assoc., Phoenix AZ

(4) Gastroenterology, Bailey Square GI, Austin TX, United States

(5) Gastroenterology, U. Hospital Pilsen-Bory, Pilsen

(6) Medicine, Dedicated Phase 1, Inc., Phoenix AZ

(7) Medicine, Charles Univ./South Bohemia Univ.

(8) Medicine, Quinta, Prague

(9) Medicine, CEPHA, Pilsen, Czech Republic

(10) Medicine, CEDRA, Austin TX, United States



This item was part of the OESOPHAGEAL, GASTRIC AND DUODENAL DISORDERS II session at Gastro 2009 UEGW/WCOG London (17th UEGW)